Global Plasma Fractionation Market Research Report: Forecast (2025-2030)

Market Definition

The market for plasma fractionation products involves the biomedical process of separating & purifying blood plasma into its individual components or fractions, including proteins and other biomolecules. This process is typically used to extract valuable therapeutic proteins & pharmaceutical products from plasma, utilized to treat various medical conditions, including immune deficiencies, clotting disorders, autoimmune diseases, and more. Plasma fractionation typically includes steps such as collection, separation, purification, sterilization, and formulation, ensuring that the final products meet strict safety and quality standards for clinical use.

Market Insights & Analysis: Global Plasma Fractionation Market (2025-30)

The Global Plasma Fractionation Market size was valued at around USD 31.18 billion in 2024 and is projected to reach USD 42.39 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 5.51% during the forecast period, i.e., 2025-30. The demand for plasma-derived therapy has been increasing worldwide, owing to the prevalence of rare disorders in the global population. In 2023, according to the Rare Disease Day Organization, around 300 million people worldwide are living with a rare disorder.

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

Also, there are several rare disorders like deficiency of factor XIII, Thrombotic Thrombocytopenic Purpura (TTP), etc., in which plasma-derived therapeutic products play a pivotal role in the treatment. Due to this amplifying demand for plasma-derived therapies for rare diseases, various companies like Grifols, Takeda, and others started innovating and developing new products for the treatment. For instance:

• In 2023, Takeda Pharmaceutical received FDA Approval to expand the use of HYQVI to treat primary immunodeficiency in Children (2-16yrs).

Additionally, with the growing demand for plasma fractionated drugs, plasma fractionation companies are also adopting advanced technologies to improve their manufacturing & increase production. Therefore, the significant investments across the world in improving the plasma fractionation technology & development of highly efficient plasma-fractionated drugs for all population groups would considerably support the plasma fractionation market growth in the coming years. Furthermore, the escalating prevalence of Hemophilia, an inherited bleeding disorder that hampers blood clotting, is a global concern with no existing cure. Individuals afflicted by this condition require lifelong treatment with expensive blood plasma therapy. Henceforth, the increasing incidence of hemophilia would create a significant opportunity for market players across the world to cater to the upcoming demand for plasma-fractionated drugs for hemophilia in the forecasted years.

Global Plasma Fractionation Market Driver:

Escalating Geriatric Population Driving the Demand for Plasma-derived Therapies – Globally, the surging geriatric population has resulted in a substantial boost in the incidences of diseases like immunodeficiency, neurological disorders, etc., which require plasma-derived therapies for treatment. The increment in the geriatric population has been attributed to the increasing life expectancy of the elderly population in various countries like China, Japan, etc., as a result of their improved healthcare infrastructure. Consequently, as the number of geriatric patients has been increasing, there has been an enhanced demand for plasma-derived therapeutic products, presenting a strong market situation for plasma fractionation manufacturers, particularly immunoglobulins and coagulation factors during historical years.

Further, in response to this growing demand on a global scale, companies specializing in plasma fractionation have proactively started investing in expanding their plasma therapy manufacturing facilities. Such strategic initiatives by companies across the world position them to better address the increasing need for improved treatment, ultimately contributing to positive growth of the Plasma Fractionation Market.

Global Plasma Fractionation Market Opportunity:

Government Support for Local Plasma-fractionated Drug Production to Drive the Market Expansion – Government support across several countries, like the UK, Indonesia, etc., to improve the plasma fractionation facilities across the country would help in improving the expansion of the Plasma Fractionation Market in the coming years. This would be mainly attributed to the reduced cost and improved quality of plasma-derived drugs, as these countries were largely dependent on the import of plasma-derived drugs. For instance:

• In 2023, according to the WHO, Indonesia is taking steps to develop its plasma fractionation program. With support from WHO's global 2023 Achilles project, Indonesia will start its local plasma fractionation program in 2024, aiming to secure a sustainable supply of safe blood and blood products.

Furthermore, healthcare systems in these countries have been rapidly evolving through increased investments and improved infrastructure. Therefore, the combination of a vast patient base and the presence of significant unmet medical requirements makes these nations highly appealing to plasma fractionation manufacturers of blood plasma products. this would create a significant opportunity for manufacturers and plasma fractionation centers to expand across these countries and address their demand in the forthcoming years.

Global Plasma Fractionation Market Challenge:

High Cost of Novel Therapies Hindering the Market Growth – The growth of plasma fractionation in the market has been hindered by the substantial costs associated with novel plasma therapies. One of the main contributors to these costs is the extensive amount of plasma required, specifically for therapies aimed at treating immunodeficiency diseases like Severe Combined Immunodeficiency (SCID), Chronic Granulomatous Disease (CGD), etc.  Furthermore, the creation of plasma therapy, involving a substantial number of plasma donations, is a costly fractionation process. Separating plasma from blood entails various intricate procedures, increasing the overall manufacturing costs of these treatments. As a result, the elevated production expenses contribute to the higher price of these drugs, affecting their adoption, particularly in developing nations, thus restricting the plasma fractionation market growth.

Global Plasma Fractionation Market Trend:

Expansion of Plasma Fractionation Plants Gaining Traction – The growing positive outcomes of plasma-derived drugs for chronic, autoimmune, and other diseases have raised the demand for plasma fractionation products in the market. The booming demand for plasma fractionation products has prompted global players in the Plasma Fractionation Market, such as Takeda Pharmaceuticals and Grifols, to embark on a trend of establishing new plasma fractionation manufacturing facilities worldwide. For instance:

• In 2022, Takeda announced an investment of nearly USD 300 million to construct a new production facility and a warehouse for plasma-derived therapies in Belgium.

This decision aligned with the increasing need for therapeutic drugs produced through plasma fractionation, such as immunoglobulin, albumin, and others, to meet rising demand. As a result, this new trend would allow companies to cater to a wider audience range across different countries, which would further support their growth in the coming years as well.

Global Plasma Fractionation Market (2025-30): Segmentation Analysis

The Global Plasma Fractionation Market study by MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment & includes predictions for the period 2025–2030 at the global levels. In accordance to the analysis, the market has been further classified as:

Based on Product:

• Immunoglobulin
  • Intravenous Immunoglobulin
  • Subcutaneous Immunoglobulin
  • Other Disease Specific Immunoglobulins (Hepatitis B Immunoglobulin, Tetanus Immunoglobulin, etc.)
• Coagulation Factors
  • Factor VIII
  • Factor IX
  • Von Willebrand Factor (vWF)
  • Prothrombin Complex Concentrates
  • Fibrinogen Concentrates
  • Factor XIII
  • Others (Factor VIIa, Factor XI, etc.)
• Albumin
  • Protease Inhibitor
  • Others (Plasminogen, Antithrombin III, etc.)

The Immunoglobulin segment held a dominant influence on the Plasma Fractionation Market, contributing to the highest share of the overall revenue. This was due to the increasing demand for immunoglobulins in the treatment of immunodeficiency diseases like AIDS, Hyper-IgM Syndrome, etc. It has been observed that over the past few years, the prevalence of these immuno-deficiency diseases has been increasing considerably. Therefore, the need for immunoglobulins has been further amplified to treat these diseases. Also, by observing the rising demand among patients, pharmaceutical companies are actively investing in the development of intravenous immunoglobulins to address these diseases to cater to their rising demand. Additionally, the growing prevalence of chronic diseases such as cirrhosis and cardiovascular conditions has also significantly bolstered the need for immunoglobulins developed through plasma fractionation.

Based on Application:

• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Rheumatology
• Others (Oncology, Pediatrics, etc.)

The Neurology segment held the major share of the Plasma Fractionation Market, owing to the rapid & effective response offered by Intravenous immunoglobulins (IVIG), compared to steroids and oral immunosuppressants. IVIG has been particularly beneficial for both peripheral and central nervous system disorders. There have been rising instances of neurological diseases and their related mortalities, which further necessitated the demand for its treatment methods. Observing this mortality rate, the need for effective plasma therapy has improved, resulting in plasma fractionation companies focusing on the research & development of plasma-fractionated drugs required to treat neurological disorders. For instance:

• In 2022, Alzamend Neuro, Inc. received a favorable written response from the FDA, outlining the path for clinical development of AL001, which is a plasma-derived drug to treat bipolar disorder, MDD, and PTSD.

Therefore, with the introduction of innovative therapies offering better results, healthcare professionals would be inclined toward plasma-fractionated drugs for treating neurological disorders.

Global Plasma Fractionation Market (2025-30): Regional Projection

Geographically, the Global Plasma Fractionation Market expands across:

• North America
• South America
• Europe
• The Middle East & Africa
• Asia-Pacific

North America emerged as the dominant player in the Global Plasma Fractionation Market. The prevalence of this dominance has been attributed to heightened awareness of the advantages of plasma, especially among the US and Canadian residents, as well as a growing occurrence of respiratory disorders. The presence of prominent industry players, the growing number of plasma collection facilities, and the efficient supply chain for plasma collection and distribution all played pivotal roles in supporting the expansion of the North America Plasma Fractionation Market.

Global Plasma Fractionation Industry Recent Development:

• In 2023, Octapharma AG received expanded FDA approval for its plasma-based product, wilate, for routine prophylaxis to reduce bleeding episodes in adults and children aged six and older.
• In 2023, Grifols, S.A. obtained FDA approval for a new immunoglobulin purification and filling facility in North Carolina, boosting its production capacity by an additional 16 million grams of plasma therapy annually.
• In 2023: Bio Products Laboratory (BPL) announced the establishment of a strategic partnership with CSI Pharmacy to offer distribution rights to BPL’s immune globulin product Gammaplex.
• In 2022: CSL invested USD 900 million to open a new plasma fractionation facility to manufacture plasma-fractionated drugs for treating hemophilia, immune system problems, burns, and other life-threatening medical conditions in Australia.

Gain a Competitive Edge with Our Global Plasma Fractionation Market Report

• Global Plasma Fractionation Pheromones Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
• This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
• Global Plasma Fractionation Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.